IL10 and inflammatory bowel disease: The results obtained in the current study indicate that DGBX significantly reduced the abnormally increased cytokines, such as IL-1B, TNF-a, IL-6, and IL-10, in the colon of the model mice and significantly alleviated the intestinal inflammatory reaction of the DSS-induced IBD model.